个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: a prospective analysis from multicenter study

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Wang Li[1,2] * ; Liang Xiaohua[1,3] * ; Cao Zhilang[4] * ; Wang Dahai[5] * ; Luo Ying[6] * ; Feng Yuan[7] * ; Luo Chong[1,2] ; Zhi Shufeng[8] ; Huang Yiling[9] ; Fan Zhidan[10] ; Wang Chaoying[11] ; Liu Haimei[12] ; Liu Jinxiang[13] ; Zhang Tianyu[14] ; Cheng Qiuting[15] ; Xie Xue[16] ; Shuai Lanjun[17] ; Rong Zanhua[8] ; Zeng Ping[9] ; Yu Haiguo[10] ; Lu Meiping[11] ; Sun Li[12] ; Yang Sirui[13] ; Zhao Dongmei[15] ; Zhang Wei[16] ; Wu Xiaochuan[17] ; Li Qiu[1,18] ; Wang Yajun[4] ; Zhang Qiuye[5] ; Yang Jun[6] ; Li Xiaoqing[7] ; Song Hongmei[14] ; Tang Xuemei[1,2] ;
机构： [1]Department of Pediatric Research Institute,Chongqing Key Laboratory of Child Infection and Immunity,Ministry of Education Key Laboratory of Child Development and Disorders,National Clinical Research Center for Child Health and Disorders (Chongqing), China International Science and Technology Cooperation base of Child development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China. [2]Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, Chongqing, China. [3]Clinical Epidemiology and Biostatistics Department, Children's Hospital of Chongqing Medical University, Chongqing, China. [4]Department of Rheumatology and Immunology, The First People's Hospital of Yunnan Province, Kunming, China. [5]Department of Pediatric Nephrology, Rheumatology and Immunology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, 266000, China. [6]Rheumatology & Immunology Department of Shenzhen Children's Hospital, Shenzhen, China. [7]Department of Rheumatology and Immunology, Affiliated Children's Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, 710068, China. [8]Department of Pediatrics, The Second Hospital of Hebei Medical University, Hebei, Shijiazhuang, China. [9]Department of Rheumatology and Immunology, Guangzhou Women and Children's Medical Center, Guangzhou, China. [10]Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing, Jiangsu Province, 210008, China. [11]Department of Rheumatology Immunology and Allergy, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China. [12]Department of Rheumatology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China. [13]Department of Pediatric Rheumatology, Immunology, and Allergy, the First Hospital of Jilin University, Changchun, Jilin province, China. [14]Department of Pediatrics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. [15]Department of Rheumatology and Immunology, Children's Hospital of Urnmqi, No.1 Jiankang Rd, TianShan Distinct, Urumqi City, Xinjiang Uyghur Automenous Region, China. [16]Pediatric Immunology and Rheumatology Department, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 611731, China. [17]Department of Pediatrics, The Second Xiangya Hospital, Central South University, Changhai, China. [18]Department of Nephrology, Children's Hospital of Chongqing Medical University, Chongqing, China.
出处：
DOI： 10.1093/rheumatology/kead406
ISSN：

关键词： systemic lupus erythematosus belimumab lupus low disease activity status clinical remission prospective study clinical evaluation

摘要：
The aim of this study is to identify whether low lupus disease activity status (LLDAS) and clinical remission (CR) of belimumab plus standard of care (SoC) therapy are achievable goals in childhood-onset SLE (cSLE).This multicentre, one arm pre-post intervention study was conducted at 15 centers in China. The primary end point was to describe the proportion of patients who achieved LLDAS and CR after 3, 6, and 12 months after treatment with belimumab plus SoC therapy. A multiple regression model was used to impute missing data. A Poisson regression model was used to calculate the effect of belimumab treatment on the reduced risk of serious diseases and the incidence of new damage.193 (92.2% female) with active cSLE from 15 centers were included. At 3, 6 and 12 months, the proportion of LLDAS (CR) was 12.4% (1.0%), 25.6% (4.5%) and 70.3% (29.7%), respectively. The mean SELENA-SLEDAI score decreased from 11.0 at baseline to 3.7, 2.9 and 1.7 at 3, 6, and 12 months. At baseline, all patients received steroids at a mean (SD) prednisone equivalent dose of 31.0 (18.2) mg/day, which decreased to 19.4 (10.8) mg/day at month 3, 12.6 (7.2) mg/day at month 6 and 6.7 (5.3) mg/day at month 12. The symptoms and immunological indicators were also significantly improved.This is the first and largest sample size prospective clinical intervention study of cSLE patients treated with belimumab in China. LLDAS and CR were attainable treat-to-target of belimumab plus SoC therapy in cSLE.© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

基金：
This work was supported National Key R&D Program of China (2021YFC2702003).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 2 区 医学
小类 | 2 区 风湿病学
JCR分区：
出版当年[2023]版：
Q1 RHEUMATOLOGY
最新[2023]版：
Q1 RHEUMATOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Pediatric Research Institute,Chongqing Key Laboratory of Child Infection and Immunity,Ministry of Education Key Laboratory of Child Development and Disorders,National Clinical Research Center for Child Health and Disorders (Chongqing), China International Science and Technology Cooperation base of Child development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China. [2]Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, Chongqing, China.
共同第一作者：
通讯作者：
通讯机构： [1]Department of Pediatric Research Institute,Chongqing Key Laboratory of Child Infection and Immunity,Ministry of Education Key Laboratory of Child Development and Disorders,National Clinical Research Center for Child Health and Disorders (Chongqing), China International Science and Technology Cooperation base of Child development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China. [2]Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, Chongqing, China.
推荐引用方式(GB/T 7714)：
Wang Li,Liang Xiaohua,Cao Zhilang,et al.Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: a prospective analysis from multicenter study[J].RHEUMATOLOGY.2024,63(5):1437-1446.doi:10.1093/rheumatology/kead406.
APA：
Wang Li,Liang Xiaohua,Cao Zhilang,Wang Dahai,Luo Ying...&Tang Xuemei.(2024).Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: a prospective analysis from multicenter study.RHEUMATOLOGY,63,(5)
MLA：
Wang Li,et al."Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: a prospective analysis from multicenter study".RHEUMATOLOGY 63..5(2024):1437-1446

相关文献

[1]贝利尤单抗联合免疫抑制剂治疗诱发肺寄生虫感染1例 [2]Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus [3]Chinese systemic lupus erythematosus treatment and research group registry IX: Clinical features and survival of childhood-onset systemic lupus erythematosus in china(Open Access) [4]Whole-genome sequencing of a monozygotic twin discordant for systemic lupus erythematosus [5]Inflammatory factor-mediated miR-155/SOCS1 signaling axis leads to Treg impairment in systemic lupus erythematosus [6]Parkinsonism as a Manifestation of Neuropsychiatric Systemic Lupus Erythematosus: A Case Report and Literature Review [7]Efficacy and Safety of Telitacicept in Early SLE [8]Cerebral Venous Sinus Thrombosis as the First Manifestation of Systemic Lupus Erythematosus [9]Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry VI: Effect of Cigarette Smoking on the Clinical Phenotype of Chinese Patients with Systemic Lupus Erythematosus [10]Increased expression of hub gene CXCL10 in peripheral blood mononuclear cells of patients with systemic lupus erythematosus

资源点击量：82479 今日访问量：0 总访问量：681 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西山区金碧路157号